文献速递妇产影像泌尿生殖US

游离DNA在卵巢癌诊断中相对于临床和超声信息的附加价值

Added value of cell-free DNA over clinical and ultrasound information for diagnosing ovarian cancer.
PubMed 文献 · Ultrasound Obstet Gynecol · 2025-08-19

这项前瞻性队列研究纳入三个肿瘤转诊中心连续招募的526例附件肿块拟手术患者,评估两种基于游离DNA的评分(全基因组Z评分和核小体评分)联合ADNEX模型临床和超声预测因子对卵巢恶性肿瘤风险的附加价值。结果显示,加入cfDNA评分后似然比有统计学意义,但AUC仅分别增加0.013和0.003,净获益、敏感度和特异度相似;在推荐10%风险阈值下,每多获得一例真阳性结果至少需要453例患者。结论认为cfDNA评分虽有统计学意义,但临床效用有限。

要点

  • 在ADNEX模型基础上加入cfDNA评分后,AUC仅增加0.013(不含CA 125模型)和0.003(含CA 125模型)。
  • 10%风险阈值下,加入cfDNA评分后净获益增加仅为0.0017和0.0020,每多一例真阳性至少需453例患者。
  • cfDNA评分联合ADNEX模型虽似然比有统计学意义,但净获益、敏感度和特异度与单用ADNEX模型相似。

核心结论

  • 尽管cfDNA评分加入ADNEX模型后似然比有统计学意义,但其在区分良恶性卵巢肿块方面相对于已有临床和超声ADNEX预测因子的临床效用有限。

研究设计与样本

  • 前瞻性队列研究,在三个肿瘤转诊中心连续招募526例拟手术的附件肿块患者,均行经阴道超声并按国际卵巢肿瘤分析术语和定义描述肿块,术前血浆提取cfDNA计算全基因组Z评分和核小体评分,拟合仅含ADNEX预测因子及加入cfDNA评分的逻辑回归模型。

诊断标准与关键数值

  • 报告了加入cfDNA评分前后ADNEX模型的似然比、AUC、敏感度、特异度及5%至40%阈值间的净获益;加入cfDNA评分后AUC增加0.013(不含CA 125的ADNEX模型)和0.003(含CA 125的ADNEX模型),10%推荐风险阈值下净获益分别增加0.0017和0.0020,每多一例真阳性结果至少需453例患者。

局限性

  • 加入cfDNA评分后AUC增加幅度小(0.013和0.003),净获益、敏感度和特异度与单用ADNEX模型相似。
  • 在推荐10%风险阈值下,加入cfDNA评分后每多获得一例真阳性结果至少需要453例患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: We previously proposed two cell-free (cf) DNA-based scores (genome-wide Z-score and nucleosome score) as candidate non-invasive biomarkers to further improve the presurgical diagnosis of ovarian malignancy. We aimed to investigate the added value of these cfDNA-based scores in combination with the clinical and ultrasound predictors of the Assessment of Different NEoplasias in the adneXa (ADNEX) model to estimate the risk of ovarian malignancy.

METHODS: In this prospective cohort study, 526 patients with an adnexal mass scheduled for surgery were recruited consecutively in three oncology referral centers. All patients underwent a transvaginal ultrasound examination, and adnexal masses were described according to the International Ovarian Tumor Analysis terms and definitions. cfDNA was extracted from preoperative plasma samples and genome-wide Z-scores and nucleosome scores were calculated. Logistic regression models were fitted for ADNEX predictors alone and after inclusion of the cfDNA-based scores. We report likelihood ratios, area under the receiver-operating-characteristics curve (AUC), sensitivity, specificity and net benefit for thresholds between 5% and 40%, to assess the diagnostic performance of the models in discriminating between benign and malignant ovarian masses.

RESULTS: The study included 272 benign, 86 borderline, 36 Stage-I invasive, 113 Stage-II-IV invasive, and 19 secondary metastatic tumors. The likelihood ratios for adding the cfDNA-based scores to the ADNEX model were statistically significant (P < 0.001 for ADNEX without CA 125; P = 0.001 for ADNEX including CA 125). The accompanying increases in AUC were 0.013 when the cfDNA biomarkers were added to the ADNEX model without CA 125, and 0.003 when added to the ADNEX model including CA 125. Net benefit, sensitivity and specificity were similar for all models. The increase in net benefit at the recommended 10% threshold estimated risk of malignancy when adding the cfDNA-based scores was 0.0017 and 0.0020, respectively, for the ADNEX model without CA 125 and the ADNEX model with CA 125. According to these results, adding cfDNA markers would require at least 453 patients per additional true-positive test result at the 10% risk threshold.

CONCLUSION: Although statistically significant, cfDNA-based biomarker scores have limited clinical utility in addition to established clinical and ultrasound-based ADNEX predictors for discriminating between benign and malignant ovarian masses. © 2025 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Vanderstichele A, Ceusters J, Fischerova D, et al. Added value of cell-free DNA over clinical and ultrasound information for diagnosing ovarian cancer. Ultrasound Obstet Gynecol. 2025. PMID: 40829165. doi:10.1002/uog.29314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。